simfo
Spezielle Immunologie Forschung + Entwicklung GmbH
simfo GmbH is a research and development facility with advanced expertise in personalized medicine, based in Bayreuth, Germany. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics in order to optimize personalized therapy. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. This allows more rapid intervention options and therefore better treatment.
In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development. Stratification of the patients by means of the maintrac® platform makes it possible to effectively distinguish responders from non-responders.
maintrac®
Circulating epithelial tumor cells
For patients, a diagnosis of cancer is a drastic event with many and varied consequences.
The challenge for the physician is to weigh up how to proceed in each individual case, since the tumors can differ from each other notably. Some tumors grow very slowly or stop growing, while others are highly aggressive.
The goal should be to prevent the proliferation of the disease. Therefore, individual treatment strategies are required and it is important to monitor the success of the treatment applied in the case of each patient.
The development of metastases, which can lead to the failure of vital organs, is crucial for the progression of the disease. These grow from cells that have moved from the tumor.
Those cells, called "circulating epithelial tumor cells" (CETCs/CTCs), can still be found in the blood years after surgery or treatment. They can contribute to the development of metastases decades after the actual cancer diagnosis.
maintrac® is a highly sensitive microscopic method for identifying these tumor cells. maintrac® precision diagnostics make it possible to utilise the dynamics and characteristics of the tumor cells. Based on these, the patient and physician can jointly make treatment decisions. maintrac® can thereby offer patients a benefit that is relevant to their survival.
